Oxford vaccine might change into the primary to get Indian regulator’s nod for emergency use

New Delhi: With preparations underway for a doable vaccine-rollout by January, the Indian drug regulator is trying on the UK, which sources consider might give its nod to the Oxford COVID-19 vaccine subsequent week, earlier than deciding on giving emergency use authorisation to the Serum Institute that’s manufacturing the photographs right here.

As soon as the UK drug regulator offers its approval to the Oxford vaccine, the knowledgeable committee on COVID-19 on the CDSCO will maintain its assembly and completely evaluation the security and immunogenicity information from the scientific evaluations carried out overseas and in India earlier than granting any emergency authorisation for the vaccine right here, official sources mentioned.


The method of granting emergency use approval for Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ might take time as its section three trials are nonetheless underway, whereas Pfizer is but to make a presentation.

“Going by this, Oxford vaccine ‘Covishield’ is prone to be the primary to be rolled out in India,”  a supply mentioned.

Serum Institute of India (SII) final week additionally had submitted some further information required by the Drug Controller Normal of India (DCGI), the sources mentioned.

Amid fears concerning the mutated variant of SARS-CoV-2 detected within the UK, authorities officers lately mentioned that it can have no affect on the potential of rising vaccines which can be being developed in India and different international locations.


Bharat Biotech, Serum Institute of India (SII) and Pfizer had utilized to the Medication Controller Normal of India  (DCGI) searching for emergency use authorisation for his or her COVID-19 vaccines early this month.

The topic knowledgeable committee (SEC) on COVID-19 of the Central Medication Commonplace Management Organisation (CDSCO) on December 9 had sought further security and efficacy information for COVID-19 vaccines of SII and Bharat Biotech after deliberating upon their functions.

The applying by the Indian arm of US pharmaceutical agency Pfizer was not taken up for deliberation as the corporate had sought extra time for making a presentation earlier than the committee.


The Pfizer vaccine has already been permitted by a number of international locations together with the UK, the US, and Bahrain.

Whereas contemplating SII’s software, the SEC had really useful that the agency ought to submit an up to date security information of section 2 and three scientific trials within the nation, immunogenicity information from the scientific trial within the UK and India, together with the end result of the evaluation of the UK Medicines and Healthcare merchandise Regulatory Company (MHRA) for grant of EUA.

As for Hyderabad-based Bharat Biotech, “after detailed deliberation, the committee really useful that the agency ought to current the security and efficacy information from the continuing section three scientific trial within the nation for additional consideration”, the SEC had mentioned.


The Pune-based SII, the world’s largest vaccine producer, has made a collaboration with the College of Oxford and AstraZeneca to fabricate the vaccine.

The SII has already manufactured 40 million doses of the vaccine, beneath the at-risk manufacturing and stockpiling licence from the DCGI, officers lately had mentioned.

Leave a Reply

Your email address will not be published. Required fields are marked *